High-Risk Pancreatic Cancer Program
Who is at high-risk of pancreatic cancer?
We have enrolled in the PRECEDE Consortium:
“The PRECEDE Consortium is a collaborative research effort by 56 academic medical centers around the world. The University of California San Diego is the academic coordinating center, led by Dr. Diane Simeone.
It is the largest effort of its kind, using a novel model of data sharing across some of the most well-known medical centers around the world. By combining data from all these sites, researchers will be able to more effectively and quickly identify methods of early detection that will result in treatment before the disease has spread.
Novel technology approved for all malignant liver tumors. Nonthermal cavitational technology presents a unique advantage over existing thermal ablation techniques in maximizing local effects while minimizing adjacent tissue destruction. Also has the potential to increase immune response to cancer; especially important in cancer such as cholangiocarcinoma that respond to immunotherapy.” (from their website)
Pancreatic Cystic Masses and Risk of Cancer
- IPMN – what is an IPMN
- High-risk features
- Worrisome features
- Need for surveillance
- Mucinous cystic neoplasms
